Summary.-In view of the relatively poor prognosis for patients after surgery for locally invasive colorectal cancer a trial of repeated systemic infusions of Corynebacterium parvum (CP) has been carried out. It is in this group of patients, with a high risk of recurrence from small residues of cancer left by the surgeon, that immunotherapy should have its optimum chance of success.
IN 1977 CANCER of the colon and rectum caused 16,462 deaths in England and Wales (Office of Population Censuses and Surveys, 1977) . Advances in surgical technique have not improved the prospects of a cure for the patient presenting with the disease. Surgical treatment in the Oxford region (Gill & Morris, 1978) gives results similar to those from Birmingham (Slaney, 1971) and Bristol (Walker, 1972) . After excision of Dukes B cancers, patients had an age-adjusted 5- year survival rate of 58%, and for Dukes C it was 27 1%. While It is against this disappointing background that consideration has been given to additional treatment after surgical excision of these cancers (MacDonald, 1976; Carter 1976) . One approach is based on a postulated role for a specific immune defence mechanism in the host with colorectal cancer, with the concept that this is depressed in these patients and might be restored to normal by appropriate immunostimulation. If a specific defence mechanism did exist in colorectal cancer (or in any cancer for that matter), tumour-specific antigens would be present and should be identifiable. Conclusive proof for this, however, is lacking. Several in vitro and in vivo studies support the view that tumour-specific antigens are present in colorectal cancer, and that they may evoke an immune response in the tumour-bearing patient (Gold & Freedman, 1965; Nairn et al., 1971; Pihl et al., 1976; Vose et al., 1981; Hollinshead et al., 1972; Bull et al., 1973; Wanebo et al., 1980 (Scott 1974 a, b) . Its effect is probably mediated by mononuclear phagocytes when the bacterium is used systemically, and CP treatment suppresses the development of many transplantable tumours (Scott, 1 974a) . Early reports of the use of CP in humans suffering from advanced cancers suggested that the treatment was well tolerated and led to prolonged remission of disease in some patients (Israel, 1975) .
In view of the poor prognosis for patients who present with Dukes B and C colorectal cancers, this group was selected for a trial of regular systemic infusions of CP over the 2 years after surgical excision of their tumours. Many relapses occur in this period, and immune stimulation might be expected to be of maximal benefit when used in a patient bearing minimal residual disease (Carter, 1976 -within a month of operation, and in each patient it wa-as planned to give 10 infusions in the 2 years after surgery. The treatment interval was monthly for the first 3 infusions, 2-monthly for the next 3, and then in the second year after surgery the last 4 w'ere given 3-monthly. Treatment usually involved an overnight stay in hospital, but some patients were allowed home within 8 h of the infusion. In our preliminary pilot study, and from other reports, it -was evident that the side-effects of i.v. CP included hypertension and hypotension. In view of this, patients who were known to suffer from cardiovascular disease, hypertension or pulmonary disease
were not considered for treatment. Patients with a history of allergy and those over the age of 75 years -were also excluded. The trial was carried out over a period of 54 months. All patients randomized into the trial have been followed up to the closing date by the Consuiltant Surgeon wNho performed the original operation. Thie diagnosis of recurrence of disease -was based in general on clinical criteria; no CEA estimations were made.
Randomization was carried out according to statistical tables supplied by the Department of Medical Statistics, Oxford University. The statistical analyses of the survival curves has been carried out by drawiing life tables and applying the log-rank test (Peto et al., 1977 (Fig. 2) . Table IV shows the principal sites where tumour recurrence first became evident. Gill et al. (1977) and Gill & Morris (1978) . This is probably explained by the selection of younger and relatively healthy patients for inclusion in the trial. The observation also emphasizes the dangers in the use of historical controls.
The Oxford retrospective study also showed that there were no significant sex differences in prognosis after surgery. It might be that the preponderance of male patients in the control group of this study has biased the results, because the overall improvement in prognosis for female patients has long been known (Gabriel, 1948) .
The death of a patient who sustained a myocardial infraction within 24 h of treatment led to concern that the trial should be stopped (Gill et al., 1977) . This patient had tolerated the first infusion well, but during the second had a marked hypotensive episode from which he appeared to recover satisfactorily. Hlowever, 12 h later he developed crushing chest pain and died with irrefutable evidence of an acute myocardial infraction. Although no further tragedies occurred after the adoption of a more rigid exclusion policy, this resulted in very low input to the trial, with the exclusion of a high percentage of otherwise suitable patients because of concern about the side-effects of CP.
At the beginning of this trial it seemed reasonable to aim for a course of infusions. Unfortunately the tolerance which was reported to build up after the first few infusions (Israel, 1975) developed only in a minority of our patients. Indeed, some patients suffered from increasingly severe side-effects. Most of the patients who did not complete the course of treatment were withdrawn by the investigating team, but 2 found the side-effects intolerable and requested that treatment be stopped.
The 8 treatment-group patients who did not receive CP comprised 1 lady who died during convalescence, and 7 who declined treatment having previously given informed consent before randomization. As a full discussion of the side-effects and nature of the proposed treatment took place before randomization, it is perhaps understandable that these patients had second thoughts about undergoing the infusions once they were discharged from hospital. No subsequent attempt was made to persuade these patients to have the treatment.
The poor outlook for Dukes B and C colorectal cancer has prompted many other clinical trials of adjuvant treatment after surgery (Li & Ross, 1976; Valdivieso & Mavligit, 1978) . In several of these, chemotherapy with 5-fluorouracil (FU) has been used, and in other trials chemotherapy was combined with attempted stimulation of the immune system (MacDonald, 1976 Anderson group), the structure of the trial must be questioned (Valdivieso & Mavligit, 1978) . In that trial patients were treated after surgery for Dukes C cancers in two ways. Some patients received repeated scarification with BCG alone, while others had the same treatment combined with oral FU. BCG treatment involved scarification weekly for 3 months, and then on alternate weeks. FU treatment involved 150 mg/M2 of the drug taken orally 4 times a day for 5 days, once every 4 weeks over 2 years. Each group had a prolonged disease-free interval, and a survival curve that matched that of a historical control group of patients who had suffered from Dukes B cancer. Since both treatment groups had similar disease-free intervals and survival times it seemed resaonable to attribute this to the BCG rather than the FU. However, these figures must be criticized because of the use of a historical control. The apparent improvement in the outcome of treatment for Dukes C patients could well have been due to other factors, for example a change in the type of patient presenting for surgery. If the survival of the control group with Dukes C lesions is carefully considered in isolation, it appears particularly poor and hence the improvement in prognosis for both treatment groups in this study may not be real.
Israel's report (1975) of the beneficial effect of systemic CP in advanced human malignancy engendered considerable enthusiasm for this approach. However, confirmation of a beneficial effect of CP in advanced cancer has not been provided from other centres. (Fisher et al., 1976; Chare et al., 1978) .
The ability of a treatment to influence the growth and spread of tumours in laboratory animals supports the investigation of its use in human malignancy. But laboratory results are not necessarily of clinical relevance. Even in laboratory animals, systemic CP has a weak action against large tumour masses, and is more effective in suppressing the development of metastases (Sadler & Castro, 1976 ) CP in our trial has not influenced the recurrence of disease.
One objection to the use of immunostimulants is the lack of specificity for target cells, and the risk of suppressing existing 8pecific defence mechanisms, e.g., increasing a population of suppressor T cells, leading to enhanced tumour growth. None of the early human studies with CP in advanced human cancers suggested that this did happen, but there was a clear need for caution in monitoring the progress of the patients in our trial (Fisher, 1978; James et al., 1978) .
The trial has now been closed. No obvious beneficial or deleterious effect of CP infusions was found in Dukes B or C colorectal cancers, as determined by patient survival, cancer recurrence and the time of recurrence. However, the small numbers studied do not allow us to exclude the possibility of there being a small effect, beneficial or deleterious, which would only be apparent with many more patients.
